“…The landscape of CF therapeutics is changing rapidly, and outcome measures used to detect disease must follow suit. With this well-designed observational study of radiographic abnormalities in infants with CF detected by NBS or clinical symptoms, Stahl and colleagues ( 13 ) continue to push forward to establish lung MRI as the standard of care for the detection of mild, asymptomatic CF lung disease.…”